Vaxxinity (VAXX) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free VAXX Stock Alerts $0.05 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?April 22, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 19, 2024 | marketwatch.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | globenewswire.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockMarch 28, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 27, 2024 | investorplace.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | globenewswire.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 7, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024February 15, 2024 | finance.yahoo.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 13, 2024 | finance.yahoo.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024February 8, 2024 | marketbeat.comVaxxinity (NASDAQ:VAXX) Shares Down 2.2% Vaxxinity (NASDAQ:VAXX) Trading Down 2.2%January 30, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 19, 2024 | finance.yahoo.comVaxxinity & UCF to Collaborate on Space Medicine ResearchJanuary 18, 2024 | finance.yahoo.comVaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaJanuary 3, 2024 | finance.yahoo.comVaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceDecember 12, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityNovember 21, 2023 | markets.businessinsider.comAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And OthersNovember 20, 2023 | foxnews.comSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successNovember 20, 2023 | msn.comResearchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 13, 2023 | finance.yahoo.comVaxxinity to Present at Upcoming November Medical and Investor ConferencesNovember 8, 2023 | finance.yahoo.comVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 10, 2023 | finance.yahoo.comPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declineSeptember 8, 2023 | marketbeat.comMovers Lab Fund I. Lp Prime Sells 25,089 Shares of Vaxxinity, Inc. (NASDAQ:VAXX) StockVaxxinity, Inc. (NASDAQ:VAXX - Get Free Report) major shareholder Movers Lab Fund I. Lp Prime sold 25,089 shares of the firm's stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $1.67, for a total value of $41,898.63. Following the completion of the transaction, the insider now owns 8,713,663 shares in the company, valued at approximately $14,551,817.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.September 7, 2023 | finance.yahoo.comDown -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)August 11, 2023 | finance.yahoo.comVaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s TreatmentAugust 10, 2023 | finance.yahoo.comVaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseaseAugust 9, 2023 | finance.yahoo.comVaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 28, 2023 | finance.yahoo.comVaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific DirectorJuly 28, 2023 | finance.yahoo.comVaxxinity Appoints Dr. Peter Powchik as Global Scientific DirectorJuly 28, 2023 | marketbeat.comLincoln National Corp Invests $93,000 in Vaxxinity, Inc. (NASDAQ:VAXX)Lincoln National Corp purchased a new stake in Vaxxinity, Inc. (NASDAQ:VAXX - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 41,070 shares of the company's stock, valued at approximatelyJuly 17, 2023 | finance.yahoo.comPromising Milestone in Neurodegenerative Disease Treatment: Vaxxinity’s UB-312 in Parkinson’s PatientsJuly 17, 2023 | finance.yahoo.comVaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s PatientsJuly 9, 2023 | marketbeat.comMcAdam LLC Buys New Stake in Vaxxinity, Inc. (NASDAQ:VAXX)McAdam LLC bought a new stake in Vaxxinity, Inc. (NASDAQ:VAXX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 46,324 shares of the company's stock, valued at approximatelyJune 22, 2023 | finance.yahoo.comPositive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s DiseaseJune 22, 2023 | finance.yahoo.comVaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine TrialJune 22, 2023 | finance.yahoo.comVaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s DiseaseMay 9, 2023 | finance.yahoo.comVaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 3, 2023 | finance.yahoo.comVaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last weekApril 24, 2023 | finance.yahoo.comWeekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro RecapMarch 28, 2023 | finance.yahoo.comVaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in AprilMarch 27, 2023 | finance.yahoo.comVaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdatesMarch 21, 2023 | finance.yahoo.comVaxxinity Joins TransCelerate Research and Development ConsortiumMarch 20, 2023 | finance.yahoo.comVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat HypercholesterolemiaMarch 2, 2023 | finance.yahoo.comVaxxinity to Present at Upcoming March Scientific and Medical ConferencesFebruary 24, 2023 | markets.businessinsider.comNektar Therapeutics (NKTR) was downgraded to a Sell Rating at JefferiesFebruary 9, 2023 | marketbeat.comFirst Republic Investment Management Inc. Buys New Position in Vaxxinity, Inc. (NASDAQ:VAXX)First Republic Investment Management Inc. bought a new stake in Vaxxinity, Inc. (NASDAQ:VAXX - Get Rating) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 199,022 shares of the company's stock, Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. VAXX Media Mentions By Week VAXX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VAXX News Sentiment▼1.440.55▲Average Medical News Sentiment VAXX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VAXX Articles This Week▼20▲VAXX Articles Average Week Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bionomics News Today Trevena News Today Can-Fite BioPharma News Today eFFECTOR Therapeutics News Today Oragenics News Today Virios Therapeutics News Today Cyclerion Therapeutics News Today Hepion Pharmaceuticals News Today Cadrenal Therapeutics News Today Shuttle Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VAXX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
